Clinical Trial Update: Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the effects of Exenatide Long-Acting Release on glucose control and safety in adults with Type 2 Diabetes Mellitus; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Bydureon (exenatide)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2012-08-17